CHAC1 and lung adenocarcinoma: The downregulation of ChaC1, along with other genes, appears to contribute to the mechanisms by which lung adenocarcinoma cells develop resistance to cisplatin, highlighting the UCA1-TXNIP axis as a potential therapeutic target for overcoming drug resistance (Zhou et al., 2020).